Apellis Pharmaceuticals (APLS) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Risk Analysis
APLS passed our risk checks.
APLS Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.52 |
| 52 Week High | US$35.72 |
| 52 Week Low | US$16.10 |
| Beta | 0.68 |
| 1 Month Change | 6.01% |
| 3 Month Change | 25.94% |
| 1 Year Change | -12.43% |
| 3 Year Change | -59.01% |
| 5 Year Change | -31.51% |
| Change since IPO | 74.77% |
Recent News & Updates
Recent updates
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Aug 14Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Jul 29
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers
May 09
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%
Apr 11Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt
Mar 14Apellis Pharmaceuticals: A Mixed Bag
Mar 05Apellis: Saved By The October Data
Dec 25There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise
Dec 15Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16Shareholder Returns
| APLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | 0.4% | -1.5% |
| 1Y | -12.4% | -0.7% | 14.4% |
Price Volatility
| APLS volatility | |
|---|---|
| APLS Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 708 | Cedric Francois | apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| APLS fundamental statistics | |
|---|---|
| Market cap | US$3.05b |
| Earnings (TTM) | -US$228.17m |
| Revenue (TTM) | US$754.65m |
Is APLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLS income statement (TTM) | |
|---|---|
| Revenue | US$754.65m |
| Cost of Revenue | US$440.76m |
| Gross Profit | US$313.89m |
| Other Expenses | US$542.07m |
| Earnings | -US$228.17m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 41.59% |
| Net Profit Margin | -30.24% |
| Debt/Equity Ratio | 290.5% |
How did APLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 22:40 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 33 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Matthew Luchini | BMO Capital Markets Equity Research |